IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v27y2009i1p25-37.html
   My bibliography  Save this article

Statin Therapy in Rheumatoid Arthritis

Author

Listed:
  • Nick Bansback
  • Roberta Ara
  • Sue Ward
  • Aslam Anis
  • Hyon Choi

Abstract

Background: HMG-CoA reductase inhibitors (statins) are potentially excellent candidate agents for patients with rheumatoid arthritis (RA). They reduce both cardiovascular risks and RA disease activity. Objective: To evaluate the potential long-term effects of statin therapy among patients with RA, and to determine their associated cost effectiveness by incorporating both the cardiovascular and the anti-rheumatic benefits. Methods: A Markov decision-analytic model was developed to simulate cardiovascular and RA disease profiles over time. The impact of statin therapy was estimated by adjusting the risk of coronary heart disease (CHD) events and changes in the RA Disease Activity Score (DAS28), based on the results of a randomized trial. The benefits (QALYs) and costs (in year 2005 values) were evaluated from a US payer perspective. A full uncertainty analysis, including a value-of-information (VOI) analysis, was undertaken to evaluate the importance of individual parameters. Results: Using a 10-year time horizon, the additional cost and QALYs of statin therapy were estimated to be $US4690 and 0.44 QALYs, respectively, resulting in an incremental cost-effectiveness ratio (ICER) of $US10 650 per QALY (95% CI 1525, 156 565). The QALY gain associated with statin therapy depended more on the anti-rheumatic effects of statin therapy than on its cardiovascular prevention effect. The VOI analysis found the long-term benefit of statin therapy (i.e. ≥12 months) and the consequent impact on quality of life to be the most uncertain and, therefore, influential parameters. Conclusion: Our analysis indicates that the dual anti-inflammatory/cardiovascular benefits of statins could make this therapy highly cost effective in RA. However, uncertainties remain in the available data, warranting further research on refining the precise RA disease-activity benefits and health-utility changes associated with statin therapy, at least over a 12-month period. Copyright Adis Data Information BV 2009

Suggested Citation

  • Nick Bansback & Roberta Ara & Sue Ward & Aslam Anis & Hyon Choi, 2009. "Statin Therapy in Rheumatoid Arthritis," PharmacoEconomics, Springer, vol. 27(1), pages 25-37, January.
    • Handle: RePEc:spr:pharme:v:27:y:2009:i:1:p:25-37
    DOI: 10.2165/00019053-200927010-00004
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.2165/00019053-200927010-00004
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.2165/00019053-200927010-00004?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Grieve, Richard & Hutton, John & Green, Colin, 2003. "Selecting methods for the prediction of future events in cost-effectiveness models: a decision-framework and example from the cardiovascular field," Health Policy, Elsevier, vol. 64(3), pages 311-324, June.
    2. Sawsan Youssef & Olaf Stüve & Juan C. Patarroyo & Pedro J. Ruiz & Jennifer L. Radosevich & Eun Mi Hur & Manuel Bravo & Dennis J. Mitchell & Raymond A. Sobel & Lawrence Steinman & Scott S. Zamvil, 2002. "The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease," Nature, Nature, vol. 420(6911), pages 78-84, November.
    3. Andrew H. Briggs & A. E. Ades & Martin J. Price, 2003. "Probabilistic Sensitivity Analysis for Decision Trees with Multiple Branches: Use of the Dirichlet Distribution in a Bayesian Framework," Medical Decision Making, , vol. 23(4), pages 341-350, July.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Ara, Roberta & Brazier, John, 2009. "Populating an economic model with health state utility values: moving towards better practice," MPRA Paper 29896, University Library of Munich, Germany.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. A. E. Ades & Karl Claxton & Mark Sculpher, 2006. "Evidence synthesis, parameter correlation and probabilistic sensitivity analysis," Health Economics, John Wiley & Sons, Ltd., vol. 15(4), pages 373-381, April.
    2. Alan Brennan & Samer Kharroubi & Anthony O'Hagan & Jim Chilcott, 2007. "Calculating Partial Expected Value of Perfect Information via Monte Carlo Sampling Algorithms," Medical Decision Making, , vol. 27(4), pages 448-470, July.
    3. Rachael DiSantostefano & Andrea Biddle & John Lavelle, 2006. "The Long-Term Cost Effectiveness of Treatments for Benign Prostatic Hyperplasia," PharmacoEconomics, Springer, vol. 24(2), pages 171-191, February.
    4. Pedram Sendi & Huldrych F Günthard & Mathew Simcock & Bruno Ledergerber & Jörg Schüpbach & Manuel Battegay & for the Swiss HIV Cohort Study, 2007. "Cost-Effectiveness of Genotypic Antiretroviral Resistance Testing in HIV-Infected Patients with Treatment Failure," PLOS ONE, Public Library of Science, vol. 2(1), pages 1-8, January.
    5. Ya-Chen Shih & Josephine Mauskopf & Rohit Borker, 2007. "A Cost-Effectiveness Analysis of First-Line Controller Therapies for Persistent Asthma," PharmacoEconomics, Springer, vol. 25(7), pages 577-590, July.
    6. Laura McCullagh & Cathal Walsh & Michael Barry, 2012. "Value-of-Information Analysis to Reduce Decision Uncertainty Associated with the Choice of Thromboprophylaxis after Total Hip Replacement in the Irish Healthcare Setting," PharmacoEconomics, Springer, vol. 30(10), pages 941-959, October.
    7. Kenneth J. Smith & Amber E. Barnato & Mark S. Roberts, 2006. "Teaching Medical Decision Modeling: A Qualitative Description of Student Errors and Curriculum Responses," Medical Decision Making, , vol. 26(6), pages 583-588, November.
    8. Naren Kumar Surendra & Mohd Rizal Abdul Manaf & Lai Seong Hooi & Sunita Bavanandan & Fariz Safhan Mohamad Nor & Shahnaz Shah Firdaus Khan & Ong Loke Meng & Abdul Halim Abdul Gafor, 2019. "Cost utility analysis of end stage renal disease treatment in Ministry of Health dialysis centres, Malaysia: Hemodialysis versus continuous ambulatory peritoneal dialysis," PLOS ONE, Public Library of Science, vol. 14(10), pages 1-16, October.
    9. Chien-Cheng Chien & Po-Huang Chen & Chi-Hsiang Chung & Chien-An Sun & Wu-Chien Chien & Ke-Hung Chien, 2021. "Association between Statins and Retinal Vascular Occlusion: A Population-Based Cohort Study," IJERPH, MDPI, vol. 18(18), pages 1-11, September.
    10. Andrija S Grustam & Nasuh Buyukkaramikli & Ron Koymans & Hubertus J M Vrijhoef & Johan L Severens, 2019. "Value of information analysis in telehealth for chronic heart failure management," PLOS ONE, Public Library of Science, vol. 14(6), pages 1-23, June.
    11. Friedemann Paul & Sonia Waiczies & Jens Wuerfel & Judith Bellmann-Strobl & Jan Dörr & Helmar Waiczies & Mareile Haertle & Klaus D Wernecke & Hans-Dieter Volk & Orhan Aktas & Frauke Zipp, 2008. "Oral High-Dose Atorvastatin Treatment in Relapsing-Remitting Multiple Sclerosis," PLOS ONE, Public Library of Science, vol. 3(4), pages 1-9, April.
    12. Jaime Gonzalez Cardona & Matthew D Smith & Jingya Wang & Leslie Kirby & Jason T Schott & Todd Davidson & Jodi L Karnell & Katharine A Whartenby & Peter A Calabresi, 2019. "Quetiapine has an additive effect to triiodothyronine in inducing differentiation of oligodendrocyte precursor cells through induction of cholesterol biosynthesis," PLOS ONE, Public Library of Science, vol. 14(9), pages 1-19, September.
    13. Mylene Lagarde & John Cairns, 2012. "Modelling human resources policies with Markov models: an illustration with the South African nursing labour market," Health Care Management Science, Springer, vol. 15(3), pages 270-282, September.
    14. Ankur Pandya & Ashley A Eggman & Hooman Kamel & Ajay Gupta & Bruce R Schackman & Pina C Sanelli, 2016. "Modeling the Cost Effectiveness of Neuroimaging-Based Treatment of Acute Wake-Up Stroke," PLOS ONE, Public Library of Science, vol. 11(2), pages 1-13, February.
    15. Celine Johanna van de Laar & Carly A Janssen & Matthijs Janssen & Martijn A H Oude Voshaar & Maiwenn J AL & Mart A F J van de Laar, 2022. "Model-based cost-effectiveness analyses comparing combinations of urate lowering therapy and anti-inflammatory treatment in gout patients," PLOS ONE, Public Library of Science, vol. 17(1), pages 1-13, January.
    16. Yuanhui Zhang & Haipeng Wu & Brian T. Denton & James R. Wilson & Jennifer M. Lobo, 2019. "Probabilistic sensitivity analysis on Markov models with uncertain transition probabilities: an application in evaluating treatment decisions for type 2 diabetes," Health Care Management Science, Springer, vol. 22(1), pages 34-52, March.
    17. Bruce Wang & Joshua A Roth & Hiep Nguyen & Eugene Felber & Wes Furnback & Louis P Garrison, 2015. "The Short-Term Cost-Effectiveness of Once-Daily Liraglutide Versus Once-Weekly Exenatide for the Treatment of Type 2 Diabetes Mellitus in the United States," PLOS ONE, Public Library of Science, vol. 10(4), pages 1-13, April.
    18. Christopher Knight & Josephine Mauskopf & Mats Ekelund & Amitabh Singh & Shiyi Yang & Robert Boggs, 2012. "Cost-effectiveness of treatment with etanercept for psoriasis in Sweden," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(2), pages 145-156, April.
    19. Charles Christian Adarkwah & Afschin Gandjour & Maren Akkerman & Silvia M Evers, 2011. "Cost-Effectiveness of Angiotensin-Converting Enzyme Inhibitors for the Prevention of Diabetic Nephropathy in The Netherlands – A Markov Model," PLOS ONE, Public Library of Science, vol. 6(10), pages 1-10, October.
    20. Regina Rendas-Baum & Min Yang & Joseph Gricar & Gene Wallenstein, 2010. "Cost-effectiveness analysis of treatments for premenstrual dysphoric disorder," Applied Health Economics and Health Policy, Springer, vol. 8(2), pages 129-140, March.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:27:y:2009:i:1:p:25-37. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.